Zepbound

Yellow tape measure with a variety of weight loss medication on blue background
Biotech

Lilly's oral GLP-1 tied to 12% weight loss in phase 3 trial

Lilly is now headed toward regulators, angling to submit approval applications for the next-gen obesity asset by the end of 2025.
Gabrielle Masson Aug 7, 2025 6:30am
obesity overweight weight loss weigh

Scholar Rock's SMA drug helps Zepbound patients retain muscle

Jun 18, 2025 9:10am
weight loss scale weigh measure tape obesity overweight

Lilly's amylin data impress with 11% weight loss, tolerability

Jun 16, 2025 4:55am
Ozempic syringe pen and measuring tape on blue background

Novo plots ph. 3 trials for next-gen obesity asset amycretin

Jun 13, 2025 10:35am
boat cutting through water

Amgen’s late-stage obesity trials expected to read out in ‘27

Mar 5, 2025 1:58pm
pipelines in the sun

Lilly's next focus: Testing incretins in neuro, immunology fields

Feb 6, 2025 2:35pm